Skip to content

Study · Randomized controlled trial · n = 20 · 2003

5 results

A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy.

Chadwick D, Pido-Lopez J, Pires A, Imami N, Gotch F, Villacian JS, Ravindran S, Paton NI

Clinical and experimental immunology1 Dec 2003Cited by 27 (Europe PMC)

PMID14632754 (opens in a new tab)DOI10.1111/j.1365-2249.2003.02331.x (opens in a new tab)PepBankPUB-14632754
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In HIV-infected adults with low CD4 counts on HAART, thymosin alpha‑1 was well tolerated and no serious adverse events occurred.

    In plain wordsIn adults with HIV and low CD4 counts on treatment, thymosin alpha‑1 was well tolerated, with no serious adverse events.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeTolerability and serious adverse events
    Study

    n = 20

    Comparator
    No injections
    Outcome group
    Adverse events · Whole body
    Studied dose
    3.2 mg twice weekly · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Thymosin alpha 1 was well tolerated and there were no serious adverse events.
    1 context sentence
    Summary · context
    Twenty clinically stable patients with viral loads <400 copies/ml and CD4 counts less than 200 cells/microl were randomized to receive 3.2 mg thymosin alpha 1 subcutaneous injections twice weekly or no injections for 12 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In HIV-infected adults with low CD4 counts on HAART, CD4 count changes at week 12 did not differ between thymosin alpha‑1 and control groups.

    In plain wordsIn adults with HIV and low CD4 counts, CD4 count changes did not differ between the thymosin alpha‑1 group and the control group.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeCD4 lymphocyte count change at week 12
    Study

    n = 20

    Comparator
    No injections
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    3.2 mg twice weekly · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    There was no significant difference between the thymosin alpha1 and control groups in CD4, CD8 and CD45 lymphocyte subset changes at week 12
    1 context sentence
    Summary · context
    Twenty clinically stable patients with viral loads <400 copies/ml and CD4 counts less than 200 cells/microl were randomized to receive 3.2 mg thymosin alpha 1 subcutaneous injections twice weekly or no injections for 12 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In HIV-infected adults with low CD4 counts on HAART, CD8 count changes at week 12 did not differ between thymosin alpha‑1 and control groups.

    In plain wordsIn adults with HIV and low CD4 counts, CD8 count changes did not differ between the thymosin alpha‑1 group and the control group.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeCD8 lymphocyte count change at week 12
    Study

    n = 20

    Comparator
    No injections
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    3.2 mg twice weekly · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    There was no significant difference between the thymosin alpha1 and control groups in CD4, CD8 and CD45 lymphocyte subset changes at week 12
    1 context sentence
    Summary · context
    Twenty clinically stable patients with viral loads <400 copies/ml and CD4 counts less than 200 cells/microl were randomized to receive 3.2 mg thymosin alpha 1 subcutaneous injections twice weekly or no injections for 12 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In HIV-infected adults with low CD4 counts on HAART, CD45 lymphocyte subset changes at week 12 did not differ between thymosin alpha‑1 and control groups.

    In plain wordsIn adults with HIV and low CD4 counts, CD45 lymphocyte subset changes did not differ between the thymosin alpha‑1 group and the control group.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeCD45 lymphocyte subset change at week 12
    Study

    n = 20

    Comparator
    No injections
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    3.2 mg twice weekly · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    There was no significant difference between the thymosin alpha1 and control groups in CD4, CD8 and CD45 lymphocyte subset changes at week 12
    1 context sentence
    Summary · context
    Twenty clinically stable patients with viral loads <400 copies/ml and CD4 counts less than 200 cells/microl were randomized to receive 3.2 mg thymosin alpha 1 subcutaneous injections twice weekly or no injections for 12 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In HIV-infected adults with low CD4 counts on HAART, PBMC sjTREC levels increased significantly with thymosin alpha‑1 compared with controls at week 12.

    In plain wordsIn adults with HIV and low CD4 counts, thymosin alpha‑1 raised T cell receptor excision circle levels in blood cells more than no injections.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreasePBMC sjTREC level at week 12
    Study

    n = 20

    Comparator
    No injections
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    3.2 mg twice weekly · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    PBMC sjTREC levels increased significantly in the thymosin alpha 1-treated patients compared to controls at week 12.
    2 context sentences
    Summary · context
    In conclusion, the increase in PBMC sjTREC levels in patients taking thymosin alpha1 may represent enhanced immune reconstitution; however, the clinical benefits and long-term consequences remain to be determined.
    Summary · context
    Twenty clinically stable patients with viral loads <400 copies/ml and CD4 counts less than 200 cells/microl were randomized to receive 3.2 mg thymosin alpha 1 subcutaneous injections twice weekly or no injections for 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.